Evidence map›Paper›PMID 31338966›Full record

ArticleJournal of cellular and molecular medicine2019

Berberine attenuates XRCC1-mediated base excision repair and sensitizes breast cancer cells to the chemotherapeutic drugs.

Xingjie Gao, Jing Wang, Meiqi Li, Jia Wang, Jian Lv, Lu Zhang, Caifeng Sun, Jiamei Ji, Wenbo Yang, Zinan Zhao and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Xingjie GaoDepartment of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Jing WangDepartment of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Meiqi LiDepartment of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Jia WangDepartment of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Jian LvDepartment of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Lu ZhangDepartment of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Caifeng SunDepartment of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Jiamei JiDepartment of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Wenbo YangDepartment of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Zinan ZhaoDepartment of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Weifeng MaoDepartment of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.ORCID 0000-0002-8632-1942
Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Berberine (BBR) is a natural isoquinoline alkaloid, which is used in traditional medicine for its anti-microbial, anti-protozoal, anti-diarrhoeal activities. Berberine interacts with DNA and displays anti-cancer activities, yet its effects on cellular DNA repair and on synthetic treatments with chemotherapeutic drugs remain unclear. In this study, we investigated the effects of BBR on DNA repair and on sensitization of breast cancer cells to different types of DNA damage anti-tumoural drugs. We found BBR arrested cells in the cell cycle S phase and induced DNA breaks. Cell growth analysis showed BBR sensitized MDA-MB-231 cells to cisplatin, camptothecin and methyl methanesulfonate; however, BBR had no synergistic effects with hydroxurea and olaparib. These results suggest BBR only affects specific DNA repair pathways. Western blot showed BBR down-regulated XRCC1 expressions, and the rescued XRCC1 recovered the resistance of cancer cells to BBR. Therefore, we conclude that BBR interferes with XRCC1-mediated base excision repair to sensitize cancer cells to chemotherapeutic drugs. These finding can contribute to understanding the effects of BBR on cellular DNA repair and the clinical employment of BBR in treatment of breast cancer.

Indexed as

Antineoplastic AgentsBerberineBreast NeoplasmsCamptothecinCell Cycle CheckpointsCell Line, TumorCell ProliferationCisplatinDNA BreaksDNA RepairDown-RegulationFemaleHumansHydroxyureaNeoplasm ProteinsPhthalazinesAntineoplastic AgentsBerberineCamptothecinCisplatinHydroxyureaNeoplasm ProteinsolaparibPhthalazinesPiperazinesX-ray Repair Cross Complementing Protein 1XRCC1 protein, humanbase excision repairBerberinebreast cancerDNA damage agentsXRCC1

Identifiers

PMID31338966
PMCPMC6787507
OpenAlexW2963380647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.